Results 101 to 110 of about 98,309 (302)

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

Haematologica, 2011
Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross, J.H. Marco Jansen, Simone de Haij, Frank J. Beurskens, Cees E. van der Poel, Lisette Bevaart, Maaike Nederend, Josée Golay, Jan G.J. van de Winkel, Paul W.H.I. Parren, Jeanette H.W. Leusen   +10 more
doaj   +1 more source

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity

, 2015
Hua-Fei Li,1–3,* Cong Wu,4,* Ting Chen,5,* Ge Zhang,1 He Zhao,1 Chang-Hong Ke,1 Zheng Xu21International Joint Cancer Institute, Translation Medicine Institute, 2Planning Division, Scientific Research Department, 3Tumor Immunology and Gene Therapy ...
Zhang G, Li H, Wu C, Xu Z,, Ke C, Chen T, Zhao H   +6 more
core  

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma

American Journal of Hematology, EarlyView.
Léa Ousset, Alban Canali, Barbara J. Bain   +2 more
wiley   +1 more source

DNA (cytosine‐5)‐methyltransferase 3A (Dnmt3a) mutations limit normal and autoreactive CD4+ T follicular helper responses and attenuate T cell‐driven joint inflammation

Arthritis &Rheumatology, Accepted Article.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased inflammatory markers. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

, 2015
Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis Núñez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste ...
Biffi S, Rampazzo E, Spretz R, Zorzet S, Núñez L, Capolla S, Lorenzon A, Tripodo C, Pozzato G, Garrovo C, Macor P   +10 more
core  

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Anti-CD20 (rituximab) treatment improves atopic eczema

, 2008
BACKGROUND: Atopic eczema (AE) is a chronic inflammatory skin disorder characterized by eczematous skin lesions, pruritus, and typical histopathologic features.
Simon, Hans-Uwe, Nikhil Yawalkar, Kostylina, Ganna, Hans-Uwe Simon, Hösli, Susanne, Dagmar Simon, Susanne Hösli, Simon, Dagmar, Yawalkar, Nikhil, Ganna Kostylina   +9 more
core   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product

, 2018
Sanjay Kumar Singh, Santosh Pokalwar, Sandip Bose, Shivika Gupta, Suhani Almal, Ranjit Sudhakar Ranbhor Sun Pharmaceutical Industries Limited, Tandalja, Vadodara 390 012, India Background: Cell surface protein, CD20, is extensively expressed on the ...
Bose S, Gupta S, Ranbhor RS, Pokalwar S, Almal S, Singh SK   +5 more
core